|
|
Treatment
of supratentorial glioblastoma multiforme with radiotherapy and a combination of
BCNU and tamoxifen: a phase II study
Napolitano M, Keime-Guibert F, Monjour A, Lafitte C, Ameri A, Cornu P, Broet
P, Delattre JY
Service de Neurologie, Division Mazarin, Hopital de la Pitie-Salpetriere, Paris,
France
From May 1990 to November 1994, 70 consecutive patients suffering from
glioblastoma multiforme were treated following surgery with conventional
radiotherapy and adjuvant IV BCNU administered alone or in combination with
tamoxifen. Twenty-five patients received BCNU alone (control group A) while 24
patients also received 40 mg of tamoxifen (TMX) PO daily (group B) and 21
received 100 mg of TMX PO daily (group C).
There were no significant differences
between the 3 groups concerning age, type of resection and median post-operative
Karnofsky performance status (KPS).
Blood toxicity over grade II occurred in
33.5% of patients receiving TMX versus 12% of patients treated with BCNU alone
(p < 0.05).
Deep venous thrombosis complications were observed in 4 patients
of each TMX group, whereas they were not observed in the control group (p <
0.04).
Median time to tumor progression (MTTP) was 35 weeks in the control group
and 27 weeks in both TMX groups B and C. Median survival time (MST) was 56, 66
and 51 weeks, respectively.
These results suggest that the addition of TMX to
standard treatment of glioblastomas does not affect the time to tumor
progression and overall survival but may increase the risk of deep venous
thrombosis or nitrosourea-induced blood toxicity.
PMID: 10845393 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10845393&dopt=Abstract
|
